Newsfeeds - Spark Newswire

2 minute read

Enanta Pharmaceuticals Initiates A Phase 2b Clinical Study Of EDP-938 In High-Risk Adults With Respiratory Syncytial Virus

Today, 5:15 PM

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the initiation of a Phase 2b,

ENTA

1 minute read

Oppenheimer Maintains Perform on Enanta Pharmaceuticals, Raises Price Target to $59

By Benzinga Newsdesk

Today, 5:15 PM

Oppenheimer analyst Jay Olson maintains Enanta Pharmaceuticals (NASDAQ:ENTA) with a Perform and raises the price target from $53 to $59.

ENTA

1 minute read

Analyst Ratings

What 13 Analyst Ratings Have To Say About Enanta Pharmaceuticals

By Benzinga Insights

Today, 5:15 PM

Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings within the last quarter:

ENTA

1 minute read

Oppenheimer Maintains Perform on Enanta Pharmaceuticals, Raises Price Target to $53

By Benzinga Newsdesk

Today, 5:15 PM

Oppenheimer analyst Jay Olson maintains Enanta Pharmaceuticals (NASDAQ:ENTA) with a Perform and raises the price target from $45 to $53.

ENTA

1 minute read

SVB Leerink Maintains Market Perform on Enanta Pharmaceuticals, Raises Price Target to $50

By Benzinga Newsdesk

Today, 5:15 PM

SVB Leerink analyst Roanna Ruiz maintains Enanta Pharmaceuticals (NASDAQ:ENTA) with a Market Perform and raises the price target from $44 to $50.

ENTA

3 minute read

Recap Of Friday’s Biotech Catalysts – End of The Day Summary

By Ragothaman Srinivasan

Today, 5:15 PM

The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ:ARQT) New Drug Application (NDA) for ZORYVE…

ABBV

1 minute read

Enanta Shares Rise On Positive Data From Initial-Stage Covid Study

By Ragothaman Srinivasan

Today, 5:15 PM

Enanta Pharmaceuticals (NASDAQ: ENTA) reported positive topline data from a Phase 1 study evaluating the safety, tolerability, and pharmacokinetics (PK) of orally administered single and multiple ascending doses of EDP-235 in healthy adult subjects.

ENTA

1 minute read

Evercore ISI Group Upgrades Enanta Pharmaceuticals to Outperform, Announces $62 Price Target

By Benzinga Newsdesk

Today, 5:15 PM

Evercore ISI Group analyst Liisa Bayko upgrades Enanta Pharmaceuticals (NASDAQ:ENTA) from In-Line to Outperform and announces $62 price target.

ENTA

1 minute read

RBC Capital Maintains Sector Perform on Enanta Pharmaceuticals, Raises Price Target to $67

By Benzinga Newsdesk

Today, 5:15 PM

RBC Capital analyst Brian Abrahams maintains Enanta Pharmaceuticals (NASDAQ:ENTA) with a Sector Perform and raises the price target from $64 to $67.

ENTA

1 minute read

This Analyst Says Arbutus’ EASL Presentations Outline Path For A Functional Cure For Chronic Hepatitis B

By Vandana Singh

Today, 5:15 PM

JMP Securities reiterates its Market Outperform rating but reduces the price target to $9 from $10 on Arbutus Biopharma Corp (NASDAQ:ABUS) after data…

ABUS